Details of the Drug

General Information of Drug (ID: DM6WN2D)

Drug Name
ABT-308
Indication
Disease Entry ICD 11 Status REF
Eosinophilic esophagitis DA24.1 Phase 2 [1]
Asthma CA23 Phase 1 [2]
Cross-matching ID
TTD ID
D0N3WN
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Antagonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Eosinophilic esophagitis
ICD Disease Classification DA24.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 4.40E-01 2.46 1
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 5.77E-05 4.14 2.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT00986037) Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma. U.S. National Institutes of Health.